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Abstract
Premutation alleles in FMR1 can cause the late-onset neurodegenerative disorder, fragile X-
associated tremor ataxia syndrome (FXTAS) and/or the fragile X-associated primary ovarian 
insufficiency in approximately 20% of heterozygotes. Heterozygotes of the FMR1 premutation 
have a higher incidence of immune mediated disorders such as autoimmune thyroid disorder, 
especially when accompanied by FXTAS motor signs. We describe the time course of symptoms 
of immune mediated disorders and the subsequent development of FXTAS in four women with an 
FMR1 CGG expansion, including three with the premutation and one with a gray zone expansion. 
These patients developed an immune mediated disorder followed by neurological symptoms that 
become consistent with FXTAS. In all patients we observed a pattern involving an initial 
appearance of disease symptoms – often after a period of heightened stress (depression, anxiety, 
divorce, general surgery) followed by the onset of tremor and/or ataxia. Immune mediated 
diseases are associated with the manifestations of FXTAS temporally, although further studies are 
needed to clarify this association. If a cause and effect relationship can be established, treatment of 
pre-existing immune mediated disorders may benefit patients with pathogenic FMR1 mutations.
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The fragile X–associated tremor/ ataxia syndrome (FXTAS) is an adult-onset progressive 
neurodegenerative disorder that affects heterozygotes for the fragile X mental retardation 1 
(FMR1) gene premutation (CGG expansion of 55-200 repeats). The FXTAS has also been 
described in some patients with a gray zone expansion (45-54 repeats) [Liu et al 2012; Hall 
et al 2011]. The symptoms of FXTAS include progressive intention tremor, cerebellar 
ataxia, autonomic dysfunction, peripheral neuropathy, psychiatric problems, executive 
function, and memory deficits followed by cognitive decline [Jaquemont et al., 2003; Coffey 
et al., 2008; Adams et al., 2007; Berry-Kravis et al., 2007]. Cranial MRI studies at the time 
of clinical presentation typically demonstrate white matter disease often in the middle 
cerebellar peduncles (MCP), the splenium of the corpus callosum and periventricular areas 
combined with atrophy of brain [Jacquemont et al., 2003; Coffey et al., 2008; Adams et al., 
2007; Berry-Kravis et al., 2007; Apartis et al., 2012].
Elevated levels of the FMR1 mRNA, observed in premutation heterozygotes are the basic 
molecular pathology in FXTAS [Tassone et al., 2007]. The increased mRNA levels cause a 
gain-of-function toxicity to cells leading to the formation of intranuclear inclusions in 
neurons and astrocytes throughout the central nervous system (CNS) and subsequent 
sequestration of critical proteins necessary for normal cell function [Garcia-Arocena et al., 
2010; Sellier et al., 2010, 2013; Hagerman et al., 2013]. Similar inclusions have been found 
in the peripheral nervous system and peripheral organs, including heart, testes, thyroid, 
adrenals and islet cells of Langerhans of those with FXTAS [Hunsaker et al., 2011]. 
Mitochondrial dysfunction also occurs in older premutation heterozygotes both with and 
without FXTAS [Ross-Inta et al., 2010; Napoli et al., 2011]. This cellular dysfunction is 
hypothesized to lead to neuronal cell death and white matter disease in the CNS [Adams et 
al., 2007; Greco et al., 2006; Hashimoto et al., 2011; Wang et al., 2013] associated with the 
clinical features of FXTAS.
The relative risk of immune-mediated disorders (IMDs) among female heterozygotes for the 
FMR1 premutation has been assessed compared to controls without the premutation. 
Autoimmune thyroid disorder and fibromyalgia [Coffey et al., 2008; Winarni et al., 2012] 
were found to be significantly increased in premutation women, particularly in those with 
FXTAS compared to age-matched controls. However, a study by Hunter et al. [2010] did not 
find an association between IMD and the premutation. There is evidence both for [Behm et 
al., 2012] and against fibromyalgia being an IMD [Schmidt-Wilcke et al., 2011; Üçeyler at 
al., 2011] but the cytokine profiles are disturbed in patients with fibromyalgia and such 
disturbances are common in those with the premutation because of miRNA dysfunction as 
described below [Sellier et al., 2013].
In the current clinical studies, the timing of the ages of onset of one or more IMDs and of 
medical, psychiatric and neurological problems were assessed in four women with an FMR1 
CGG expansion. Each experienced periods of heightened stress, including anxiety, 
depression, surgery, and chemotherapy, which are hypothesized to act as triggers for the 
onset of their IMD symptoms and/or FXTAS. Due to this mixture of relatively ill-defined 
symptoms of anxiety, pain, fibromyalgia, and chronic fatigue syndrome, which are often 
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considered to be functional, medical or psychiatric problems, it is sometimes difficult for 
physicians to understand the etiology and provide adequate treatment. In the current report, 
we describe the time course of the occurrence of IMDs, medical or psychiatric problems and 
FXTAS along with potential triggers, in an effort to understand the natural history of these 
illnesses in this population.
PATIENTS AND METHODS
The four patients in this study were recruited through the Fragile X Treatment and Research 
Center, MIND Institute at University of California, Davis Medical Center and who 
participated in our premutation studies. Each patient signed an informed consent approved 
by our UC Davis IRB. The medical assessment included a developmental, psychological, 
neurological, and medication history, and a detailed medical and neurological examination.
These patients were selected for reporting because they had a recent study visit and they 
were found to have an autoimmune dysfunction with symptoms of FXTAS. Each patient 
was considered to have an IMD if diagnosed and treated for such by a physician and the 
medical records were obtained. Molecular measures included CGG repeat size in FMR1 and 
activation ratio (AR), which expresses the percentage of cells that have the normal allele on 
the active X chromosome, as described [Tassone et al., 2008].
CLINICAL REPORTS
Patient1
(Timeline 1) was a 42-year-old woman, carrying alleles of 30 and 102 CGG repeats and an 
AR of 0.54. Her maternal grandfather and mother were found to be heterozygotes of the 
premutation and both had FXTAS. The proband developed chronic abdominal pain, 
cramping and bloody diarrhea in her late teens, which was diagnosed as Crohn’s disease. At 
age 19, she was under stress due to her marriage plans and her mother’s ill health. After 
marriage she reportedly suffered from hypothyroidism and multiple miscarriages, four of 
which were documented in her twenties. She developed gestational diabetes at age 27, which 
persisted post pregnancy, also post-partum depression.
In her 30’s, she suffered from widespread persistent muscle pain that was painful to touch 
leading to a diagnosis of fibromyalgia; cessation of menses, which was diagnosed as 
premature ovarian failure and a painful, swollen toe that was identified as gout. She 
developed a red malar rash, intermittent at first and then the rash persisted with sun exposure 
in her mid-30s and this was thought to be related to lupus by her rheumatologist. Her 
antiphospholipid antibody level was low to medium positive with an intermittent antinuclear 
antibody (ANA) positivity and a consistently increased C-reactive protein at age 40. Other 
stress involved her three children who were diagnosed with FXS as well as her husband’s 
chronic obstructive pulmonary disease requiring chronic oxygen therapy.
A hand tremor was first noticed at age 35. On examination, the tremor was subtle during 
finger-to-nose touching and there was a mild degree of ataxia with impaired tandem 
walking. This intention tremor worsened in her late thirties and interfered with handwriting 
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and typing. After a car accident at age 37, her depression worsened, aggravated by the lack 
of child support. Her ataxia progressed with two to three falls per month and she 
subsequently developed problems with memory beginning at age 39. She was unable to 
tandem walk at age 42.
Her cranial MRI showed a mild degree of atrophy and mild periventricular white matter 
disease but she did not have the middle cerebellar peduncle (MCP) sign of white matter 
involvement at age 41. Her lumbar spine had minor spondylosis at several levels.
After an unsuccessful trial with venlafaxine and mirtazepine for depression and anxiety in 
her late 30s and early 40s, she experienced some relief from pain and depression with 
duloxetine. Her other medications include metformin and saxagliptin for diabetes, 
gabapentin, acetaminophen with codeine for pain, and colchicine for gout.
Patient 2
(Timeline 2) was a 58-year-old Caucasian woman, with FMR1 alleles of 31 and 100, 113 
CGG repeats with an AR of 0.69. Her premutation was mosaic in repeat size with some cells 
having 100 repeats and other cells with 113 repeats. As a child, she reported that she was 
extremely shy with mildly obsessive-compulsive behavior and fingernail biting when 
anxious. She experienced post-partum depression after her first pregnancy at age 34 and this 
pregnancy was followed by development of arthritic symptoms. She complained of muscle 
pain and tenderness to touch, diagnosed as fibromyalgia at age 41; symptoms were 
alleviated by exercise.
She had arthroscopy of the left knee at age 41 for osteoarthritis, cholecystectomy at the age 
of 42 with general anesthesia. Neurological symptoms began 1 month after surgery. She had 
daily complaints of tingling and numbness in her hands associated with pain in her wrists 
that progressed to bilateral carpal tunnel syndrome. At age 48 years, she developed bilateral 
intermediate uveitis.
Symptoms of ataxia and difficulty with tandem walking were first seen in her early fifties 
and she also noticed intermittent resting and intention tremor in both arms. This was 
accompanied by urinary incontinence and development of irritable bowel syndrome. She 
underwent a hysterectomy and bladder lift procedure at age 53. She reported mild memory 
and attention problems after a total knee replacement surgery at age 55.
Viral titers for the Ebstein Barr virus were present at age 56, although the monospot test for 
infectious mononucleosis was non-reactive. She was evaluated for sarcoidosis based on her 
eye findings. A chest CT scan showed enlarged mediastinal lymph nodes that were non-
caseating granulomas on biopsy, consistent with a diagnosis of sarcoidosis at age 56. She 
had no major pulmonary symptoms and her pulmonary functions were normal. She 
underwent a pars plana vitrectomy at age 56 and a cataract surgery at age 57, without change 
in vision post-surgery.
Her cranial MRI findings at age 50 showed extensive non-specific periventricular deep 
white matter hyperintensities subcortically at the gray/ white matter junctions of the frontal 
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and parietal lobes. Additional white matter hyperintensities were identified in the 
periventricular regions of the frontal lobes.
Patient 3
(Timeline 3) was a 71-year-old retired elementary school teacher with alleles of 26 and 60 
CGG repeats, and an AR of 0.40. At age 35, she experienced muscle pain and soreness. She 
was diagnosed with hypothyroidism at age 50; age 59, she experienced worsening muscle 
pain, particularly in her arms, shoulders, back and legs, which was then diagnosed as 
fibromyalgia. She was ANA positive and was also diagnosed with Sjögren’s syndrome (with 
dry eyes and mouth and a positive SSA). She underwent surgery just prior to the diagnosis 
of fibromyalgia for a rotator cuff injury followed by cervical spine surgery for disc 
herniation. The fibromyalgia symptoms worsened after the surgeries.
She experienced considerable stress at home in her 60s due to conflicts between her son with 
learning disabilities and her husband. She also had chronic fatigue and she could only 
perform her daily activities such as dressing by taking breaks in between tasks. Depression 
was diagnosed at age 64 and she experienced partial relief of her symptoms with sertraline. 
Due to her pain symptoms, amitriptyline was added to sertraline, which significantly 
relieved her chronic pain, chronic fatigue and fibromyalgia symptoms. She was also 
diagnosed with Raynaud’s disease, although her symptoms were mild since she lived in 
warm climate.
About two months after her two surgeries in her sixties, she experienced a mild degree of 
ataxia. Her ataxia was stable until the age of 68, when she was diagnosed with breast cancer 
and underwent surgery, chemotherapy and radiation therapy. After this treatment her chronic 
fatigue syndrome came back and her ataxia worsened dramatically. At age 68, she 
developed an intention tremor and problems with her memory, particularly word retrieval 
and her handwriting worsened. She had multiple falls at age 69 and she started using a cane. 
She developed arthritic pains in her fingers, dislocation of her left thumb with difficulty 
grasping objects and a significant right foot deformity. Her rheumatoid factor was positive. 
She experienced some relief from these pain symptoms with tramadol. She also had 
complaints of numbness and tingling in her feet and arms beginning at age 69.
She was on a trial with memantine for FXTAS and had noticed some improvements in her 
balance and memory. Her other medications included gabapentin for pain in her legs, 
anastrazole for her breast cancer follow-up, risedronate for osteoporosis, occasional 
fluticasone nasal spray for allergies, and multivitamins. She had a diagnosis of probable 
FXTAS.
Patient 4
(Timeline 4) was a 69-year-old Caucasian woman with an FMR1 gray zone allele of 52 
CGG repeats in addition to her normal allele of 32 repeats. She reported anxiety symptoms 
in her school years with decreased sleep during periods of stress and frequent nighttime 
awakenings. This was followed by muscle pain and tenderness. She also had a history of 
depression and a psychiatric hospitalization due to attempted suicide in her early 20’s. She 
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reportedly developed hypothyroidism and migraine headaches requiring emergency room 
evaluation. This was associated with an aura (blurred central vision) and right-sided facial 
numbness. At age 35, her muscle aches and soreness worsened and she complained of 
increasing pain sensitivity even to light touch, after which a diagnosis of fibromyalgia was 
made.
She experienced symptoms of dry mouth, swallowing difficulties and joint pains at 42 years 
of age and had intermittent ANA and SSA positivity. She was diagnosed with a mixed 
connective tissue disease although lupus was suspected but was not diagnosed. She 
developed rheumatoid nodules on her feet and fingers with dislocation of her right thumb in 
her 50’s. She was in a car accident at age 58, which led to extreme back pain and a disc 
prolapse. She later developed Type II diabetes mellitus at age 60 years.
Problems with memory, auditory processing and visual short-term memory began at age 65, 
followed by ataxia with listing to one side. Intention tremor and bladder incontinence began 
at age 67 in addition to urinary urgency and frequency. She also experienced anorgasmia, 
beginning at age 67. During periods of stress, she noticed a significant decrease in her 
energy level. At age 69, she had arthroscopic surgery for a meniscal tear involving general 
anesthesia, a few weeks after which her tremor, handwriting and balance problems 
worsened. At the time of her clinical visit, she had intermittent numbness and tingling in her 
lower extremities and difficulty walking on a hard floor because of pain in her feet.
Her cranial MRI showed white matter hyperintensities in her insula and small areas scattered 
in the deep cortex with mild to moderate atrophy of the cerebral cortex and cerebellum, but 
no MCP sign. She met criteria for probable FXTAS although she had only a gray zone 
allele.
DISCUSSION
Initially, FXTAS was thought of principally as a CNS disorder with a primary motor 
component of an intention tremor and ataxia and concomitant white matter disease and 
global brain atrophy [Jacquemont et al., 2003; Adams et al., 2007; Brunberg et al., 2002]. 
However, it is now clear that FXTAS is much broader, with significant non-motor 
components, such as cognitive decline/ dementia and related neuropsychiatric involvement 
[Tassone et al., 2000; Seritan et al., 2008; Bourgeois et al., 2009] and peripheral nervous 
system involvement including neuropathy and autonomic dysfunction [Hunsaker et al., 
2011]. Although fewer women than men will develop FXTAS, it appears that female 
heterozygotes with and without FXTAS, may have a greater tendency to develop certain 
types of medical disorders, particularly immune mediated dysfunction , hypertension, and 
fibromyalgia [Coffey et al., 2008; Winarni et al., 2012; Leehey et al., 2011]. The 
pathogenesis is likely related to a gain-of-function toxic effect from elevated levels of the 
expanded CGG-repeat FMR1 mRNA, which is present in all patients with the premutation 
[Tassone et al., 2000; Greco et al., 2002; Tassone et al., 2007]. This is thought to cause 
psychiatric problems such as depression and anxiety [Bourgeois et al., 2009; Roberts et al., 
2009], fragile X-associated primary ovarian insufficiency (FXPOI) [Sullivan et al., 2005], 
and autonomic dysfunction [Coffey et al., 2008] along with FXTAS [Adams et al., 2007].
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The expanded CGG repeat in the FMR1 mRNA in those with the premutation is thought to 
sequester proteins including KHDRBS1/Sam68 and DGCR8/Drosha that are important for 
diverse cellular functions, including maturation of miRNAs. As a consequence of their 
sequestration, miRNA dysregulation has been observed in those with the premutation 
[Sellier et al., 2013]. Given the role of miRNAs in the physiology of immune system 
including the fine-tuning of T cell reactivity to antigens and of antibody response [Lu L-F et 
al., 2009], it is possible that dysregulation of specific miRNAs may lead to impaired 
tolerance against self-antigens and to the development of autoimmune diseases. Moreover, 
dysregulation of miRNAs may lead to sustained inflammation, which is a hallmark of 
chronic inflammatory diseases [Sonkoly et al., 2009]. RNA toxicity in premutation neurons 
leads to upregulation of heat shock proteins (e.g. : Hsp70 and αβ-crystallin) [Garcia-
Arocena et al., 2010; Wu et al., 2004], which themselves may stimulate immune 
dysregulation [Georgopoulos et al., 1993]. Hsp 70, whose expression has been found 
dysregulated in FXTAS [Garcia-Arocena et al., 2010] and in the premutation animal model, 
is involved in binding antigens and presenting them to the immune system [Nishikawa et al., 
2008]. Finally, the sequestration of proteins important for splicing messages including 
KHDRBS1 and the subsequent mis-splicing of a variety of messages is also known to lead 
to many forms of autoimmune diseases [Evsyukova et al., 2010].
Our previous findings indicate that there is increased incidence of IMDs in females with the 
premutation and FXTAS than those female heterozygotes without FXTAS [Winarni et al., 
2012]. Here we report four patients, three females with the premutation allele and one 
woman with a gray zone allele; all demonstrating IMD and subsequent development of 
FXTAS. We have included a woman with a gray zone allele because FXTAS has been 
reported in this repeat range [Hall et al., 2012; Liu et al., 2012], suggesting that RNA 
toxicity can lead to FXTAS also in gray zone heterozygotes.
In these four patients we observed a temporal link between IMD symptoms and onset of 
FXTAS, where a pattern is emerging with onset of IMD, such as autoimmune thyroid 
disease, Sjögren’s syndrome, lupus-like symptoms, or related problems such as 
fibromyalgia, chronic fatigue syndrome or inflammatory bowel disease, followed by 
development of tremor and/or ataxia. We hypothesize that IMDs or related disorders could 
accelerate the development of FXTAS by a variety of mechanisms such as enhancing 
oxidative stress, further dysregulating miRNA levels or enhancing microglia activation 
[Greco et al., 2008]. Although there is controversy as to whether fibromyalgia is indeed an 
IMD [Schmidt-Wilcke et al., 2011], fibromyalgia patients demonstrate a decreased cytokine 
response in stimulated peripheral blood mononuclear cell cultures, thereby implying 
impaired cell-mediated immunity [Behm et al., 2012]. All of the patients with fibromyalgia 
reported here also had other IMD and these problems occurred before the onset of FXTAS.
The presence of stressors such as anxiety, depression, divorce, accidents as well as surgery 
involving general anesthesia are hypothesized to act as triggers for the development of IMD 
symptoms and/ or the onset of FXTAS [Hagerman et al., 2013]. Emotional responsiveness, 
anxiety, depression and long-term memory are thought to be influenced by the RNA toxicity 
manifested by the FXTAS intranuclear inclusions that are abundant in the amygdala and 
hippocampus [Greco et al., 2002; 2006]. Amygdala dysfunction may underlie the social 
Jalnapurkar et al. Page 7













deficits in some individuals with the premutation [Farzin et al., 2006; Jakala et al., 1997; 
Hessl et al., 2005, 2007]. Cranial MRI studies have shown that increased levels of anxiety 
are associated with a decrease in the size of the hippocampus in women with the 
premutation [Jakala et al., 1997; Adams et al., 2010]. Loss of hippocampal volume may also 
be associated with mood disorders seen in FXTAS (depression, irritability) [Greco et al., 
2002; Bacalman et al., 2006].
There is evidence of hypothalamic-pituitary-adrenal axis dysfunction, with inclusions found 
in all three locations in humans and the premutation mouse model [Brouwer et al., 2008; 
Greco et al., 2007; Louis et al., 2006; Hunsaker et al., 2011] leading in turn to enhanced 
release of the stress hormone cortisol [Brouwer et al., 2008]. Cortisol dysregulation and 
stress can lead to inflammation and activation of the immune system [Chang et al., 2009]. 
Perhaps the stress that these women experience can further accelerate the onset of FXTAS.
Adults presenting with immune mediated disorders and symptoms of FXTAS may not know 
the specifics of their medical histories. They may struggle – as some of our patients did – 
with an unassembled and incomplete puzzle of various immune mediated disorders and 
neurological symptoms that may be related to the FMR1 premutation. We recommend that 
further research in women with the premutation include the variety of medical problems that 
may be related to the premutation and the temporal sequence of events that may accelerate 
the onset of FXTAS, particularly immune mediated disorders. Such research may lead to 
earlier interventions that may decrease the prevalence of FXTAS in this population of 
women.
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Time course of immune mediated symptoms followed by onset of neurological symptoms/
FXTAS along with the potential triggers in a 42-year-old female heterozygote with 102 
CGG repeats and AR of 0.54
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Time course of immune mediated symptoms followed by onset of neurological symptoms/
FXTAS along with the potential triggers in a 58-year-old female heterozygote with 100, 113 
CGG repeats and AR of 0.69
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Time course of immune mediated symptoms followed by onset of neurological symptoms/
FXTAS along with the potential triggers in a 69-year-old female heterozygote with an 
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